Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Silexion Therapeutics ( (SLXN) ).
On September 26, 2025, Silexion Therapeutics Corp entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, allowing the company to sell up to $13.17 million worth of ordinary shares through Wainwright. This agreement provides flexibility for Silexion to raise capital as needed, potentially impacting its financial strategy and market position, while adhering to regulatory requirements.
The most recent analyst rating on (SLXN) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.
Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Silexion Therapeutics Corp operates in the biopharmaceutical industry, focusing on the development and commercialization of therapeutic products. The company is engaged in offering innovative solutions to address unmet medical needs in various markets.
Average Trading Volume: 405,601
Technical Sentiment Signal: Sell
Current Market Cap: $8.19M
For a thorough assessment of SLXN stock, go to TipRanks’ Stock Analysis page.